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Abstract The leukotriene A 4 hydrolase is a central enzyme in 
leukotriene 84 formation. Unlike 5-1ipoxygenase, l ukotriene A4 
hydrolase activity is present in normal human epidermis, where 
it is likely to be involved in transcellnlar lenkotriene formation. 
In this study the leukotriene A 4 hydrolase was purified from 
human epidermis and human cultured keratinocytes and com- 
pared with leukotriene A 4 hydrolase from human neutrophils. To 
purify lenkotriene A 4 hydrolase from human epidermis a new 
non-specific affinity chromatography column, with the lenkotri- 
ene A 4 hydrolase inhibitor bestatin coupled to AH-Sepharose, 
was introduced. The epidermal ieukotriene A 4 hydrolase was pu- 
rified to apparent homogeneity and the molecular weight was 
determined to be approximately 70,000 Da by SDS-PAGE. The 
pI was 5.1-5.4 for the epidermal as well as the keratinocyte and 
neutrophil leukotriene A4 hydrolase, as determined by chromato- 
focusing. Only minor differences in the amino acid composition 
were seen between the three enzyme sources. The optimal pH for 
the hydrolase activity was 7.5-8.5 for the epidermal and neutro- 
phil leukotriene A4 hydrolases. Finally, it was also shown that the 
epidermal enkotriene A 4 hydrolase undergoes uicide inactiva- 
tion when transforming leukotriene A4 into leukotriene B4. It was 
concluded that there is a close resemblance between the epidermal 
lenkotriene A 4 hydrolase and the hydrolase found in other cell 
types. Therefore, the human epidermis may be a good model for 
the in vivo study of transcellular lenkotriene formation. 
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1. Introduction 
The biosynthesis of the potent proinflammatory compound 
leukotriene B4 (LTB4) requires the sequential transformation f
arachidonic acid by the 5-1ipoxygenase (5-LO) and leukotriene 
A 4 hydrolase, the latter catalyzing the hydrolysis of the unstable 
epoxide leukotriene A4 (LTA4) into LTB4. Several inflamma- 
tory cells, such as polymorphonuclear leukocytes (PMNs), 
monocytes/macrophages nd mast cells, contain the 5-1ipoxyge- 
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nase (5-LO) enzyme as well as the LTA4 hydrolase, and can, 
therefore, synthesize LTB4 from arachidonic acid. Recently, 
LTA4 hydrolase activity has been detected in cell types not 
showing 5-LO activity [14]. It has, therefore, been speculated 
that the LTA 4 hydrolase plays a role in transcellular metabo- 
lism, in which LTA 4 is formed in one cell type and then trans- 
ferred to, and further metabolised in, another cell lacking the 
5-LO enzyme [5]. Transcellular metabolism in leukotriene for- 
mation has been shown to take place in vitro between mon- 
ocytes and lymphocytes [6] and between eutrophils and endo- 
thelial cells, erythrocytes, platelets and human bronchoalveolar 
lavage fluid [4,7,8,9]. Recently, we and others have shown that 
neutrophils and cultured keratinocytes also interact in LTB4 
formation [1,3]. Furthermore, the enzyme has recently been 
identified and sub-fractionated in human epidermis [10,11]. 
The LTA4 hydrolase has been purified and characterized 
from several different issues and cell types, such as guinea pig 
lung [12], guinea pig liver [13], human lung [14,15], human 
neutrophils [16], human erythrocytes [2], rat neutrophils [17] 
and the B-lymphocytic ell line Raji [18]. Furthermore, the 
cDNA clone coding for LTA4 hydrolase has been isolated from 
human placenta [19], human spleen [20] and rat mesangial cells 
[21], and the human LTA4 hydrolase cDNA has been expressed 
in Escherichia coli [22] and in cultured Spodoptera frugiperda 
insect cells [23]. 
Recent, results by Bigby et al. [24] have indicated that the 
kinetic behavior of the LTA 4 hydrolase from transformed 
human airway epithelial cells (BEAS-2B) is different from that 
of neutrophils. Furthermore, the human erythrocyte LTA4 hy- 
drolase [2] varies in terms of molecular weight from the LTA4 
hydrolase from other cell sources. In the guinea pig lung, two 
catalytically active forms of the LTA4 hydrolase are found 
depending on the presence or absence of SH-reducing agents 
[12]. This dependence was not observed in the human B-lym- 
phocytic ell line Raji [18], although two kinetic patterns of the 
enzyme were observed. In contrast, the two divergent forms of 
the LTA 4 hydrolase observed in the Raji cell line were different 
according to resistance to heat treatment. 
The purpose of the present study was to purify and further 
characterize the epidermal LTA 4 hydrolase. We purified human 
epidermal and human keratinocyte LTA4 hydrolase to appar- 
ent homogeneity, and compared it to human neutrophil LTA4 
hydrolase with regard to amino acid composition and hydro- 
lase activity. Furthermore, in the purification procedure we 
introduced a new non-specific affinity chromatography column 
with the protease inhibitor bestatin coupled to AH-Sepharose. 
This step takes advantage of the fact that bestatin is a reversible 
inhibitor of LTA 4 hydrolase. 
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2. Materials and methods 
2.1. Materials 
The LTA4-methyl ester was obtained from Cascade Biochem Limited 
(Reading, England). Authentic LTB 4 was from Cayman Chemicals 
(Ann Arbor, MI). Trizma hydrochloride (Tris-HC1), trypsin, dithio- 
threitol (DTT) and bestatin were all from Sigma Chemical Co. 
(St. Louis, MO). Organic solvents were all high-performance liquid 
chromatography (HPLC) grade from Merck (Darmstad, Germany). 
Human serum albumin (HSA) was obtained from Nordisk Gentofte 
(Bagsvaerd, Denmark). The low-calcium keratinocyte growth medium 
(KGM) from Gibco (Grand Island, NY) was serum free. RPMI 1640 
medium was from Gibco, and culture dishes and Centricon-30 were 
from Life Technologies (European Division, Paisly, Scotland, UK). 
Fetal calf serum (FCS) was from AH Diagnostics (Aarhus, Denmark). 
The immobilon-P transfer membrane was from Millipore Corp. (MA, 
USA). Q-Sepharose (fast flow), AH-Sepharose 4B, phenyl-Sepharose 
C1-4B, PBE 94 and polybuffer 74 were all from Pharmacia Fine Chem- 
icals AB (Uppsala, Sweden). 
2.2. Preparation of human epidermis 
Keratomed skin specimens were obtained from skin samples of pa- 
tients undergoing plastic surgery as previously described by us [25]. The 
isolated keratome specimens were chopped into small pieces, homoge- 
nized in 50 mM Tris-HCl buffer, 1 mM DTT (pH 7.6) using a Kine- 
matic AG Polytron (3 × 10 s on ice) and finally centrifuged at 
lO0,O00xg at 4°C for 1 h. 
2.3. Neutrophil preparation 
Human neutrophils were isolated from buffy coats as previously 
described [26]. After isolation the cells were counted, resuspended in 
50 mM Tris-HC1 buffer, 1 mM DTT (pH 7.6), ultrasonicated (3 × 10 
s on ice) to produce lysis, and finally centrifuged at 100,000 x g at 4°C 
for 1 h to obtain the cytoplasmic fraction. 
2.4. Cultures of human keratinocytes 
Cultures of human keratinocytes were prepared as previously de- 
scribed [1]. The cultures were used during the first passage. When 
sub-confluent, the cell cultures were incubated at 37°C in phosphate 
buffered saline (PBS) (pH 7.0) containing 0.1% trypsin and 0.1% glu- 
cose for 7 min to release the cells. After replacing the incubation me- 
dium with RPMI containing 2% FCS, the cells were centrifuged at 
800 × g for 10 min and then washed twice in Tris-HC1 buffer, 1 mM 
DTT (pH 7.6) before counting. Finally, the cells were resuspended in 
Tris-HCl buffer, 1 mM DTT (pH 7.6), ultrasonicated (3 x 10 s on ice) 
to produce lysis, and centrifuged at 100,000 xg at 4°C for 1 h. 
2.5. Purification of LTA~ hydrolase 
All the following procedures were carried out at 4 ° C. 
Step 1. The 100,000 × g supernatant of 30 g homogenized pidermis 
was subjected to ammonium sulphate fractionation. The precipitate 
formed between 40 and 70% saturation of ammonium sulphate was 
dissolved in 8 ml of 20 mM Tris-HCl buffer/1 mM DTT (pH 8.3) (buffer 
A) and then dialyzed against wo changes of 1 1 of buffer A. 
Step 2. The dialyzed sample was applied to a Q-Sepharose column 
pre-equilibrated with buffer A, and eluted with a 300 ml linear gradient 
of 0-300 mM KC1 in buffer A with a flow rate of 5 ml/min. Fractions 
were collected at 1 min intervals and assayed for LTA 4 hydrolase 
activity by determing the capacity to transform LTA 4 (30 nmol) into 
LTB 4. The active fractions were pooled and the buffer was changed to 
10 ml of 50 mM Tris-HC1 buffer, 1 mM DTT/125 mM KCI (pH 8.0) 
(buffer B) using Amicon YM10 to concentrate he sample to 10 ml. To 
remove the last 10 ml of buffer A a Centricon-30 was used. 
Step 3. A column with bestatin coupled to AH-Sepharose 4B was 
made. This was done in accordance with the principles previously 
described for affinity chromatography [27]. Briefly, AH-Sepharose 
equilibrated with 0.5 M NaCI was mixed with a solution containing 
bestatin dissolved in a mixture of ethanol and water adjusted to pH 4.5. 
The coupling reaction was initiated by activation of the free amino 
group on AH-Sepharose by carbodiimide hydrochloride dissolved in 
water and adjusted to pH 4.5, and the reaction was allowed to take 
place at room temperature for 24 h. Finally, the excess ligand, urea 
derivatives and unreacted carbodiimide were washed out with the same 
mixture of ethanol and water as used for dissolving bestatin. 
The collected sample was then applied to the column pre-equilibrated 
with buffer B and allowed to recirculate over the column for 25 min 
with a flow rate of 1 ml/min. Then the KCI concentration in buffer B 
was raised to 175 mM for 12 min before the enzyme was eluted with 
500 mM KCI in buffer B. Fractions were collected every 2 min and 
assayed for LTA4 hydrolase activity by incubation with LTA4 (30 nmol) 
and the active fractions were pooled. Finally the buffer was changed 
to 0.1 M Tris-HC1, 1 M (NH4)2SO4, 1 mM DTT (pH 7.2) (buffer C) 
using Amicon and Centricon. 
Step 4. The enzyme sample was then applied to a phenyl-Sepharose 
column equilibrated with buffer C, and eluted with a 20 ml linear 
gradient between buffer C and a 0.1 M Tris-HCl buffer, 1 mM DTT 
(pH 7.6) with a flow rate of 0.5 ml/min. Fractions were collected at 
1 min intervals and assayed for LTA4 hydrolase activity. The active 
fractions were collected, the buffer was changed to buffer B, and the 
sample was re-applied to the column with bestatin coupled to Sepharose 
in the same way as described instep 3. The enzyme obtained is referred 
to as the purified human epidermal LTA4 hydrolase and was stored in 
50 mM Tris-HCl buffer, 1 mM DTT (pH 7.6). 
When the LTA4 hydrolase was purified from human neutrophils 
(10 × 109 cells) and human cultured keratinocytes (109 cells) the column 
with bestatin coupled to Sepharose was not used. With these cells the 
above mentioned steps 1, 2 and 4 were followed by change of the buffer 
to 25 mM bis-Tris-HC1 buffer, 1 mM DTT (pH 6.3) (buffer D) and 
application to a PBE 94 column preequilibrated with buffer D. Chro- 
matofocusing was done by eluting (0.5 ml/min) with 10% polybuffer 
(PBE) 74 adjusted to pH 4 with HCI. The collected active fractions were 
pooled, the buffer was changed to 50 mM Tris-HCl buffer, 1 mM DTT 
(pH 7.6), and the enzyme fractions obtained were used in subsequent 
experiments a the purified LTA4 hydrolase from human neutrophils 
and cultured human keratinocytes. Attempts to purify the epidermal 
LTA4 hydrolase with these methods were also carried out. 
2.6. Assay of LTA 4 hydrolase activity 
Free LTA4 used in the incubations was prepared from LTA4-methyl 
ester as previously described [1,28], and the protein content of the 
different fractions were determined according to Bradford [29] using 
bovine serum albumin as standard. Variable amounts of protein were 
preincubated in a total volume of 1 ml of 50 mM Tris-HCl (pH 7.6) 
containing 1mM DTT and 1 mg albumin at 37°C for 10 min. Then 
LTA 4 (30 nmol) in 2/.tl MeOH/NaOH was added and incubations 
carried out for 1 min. Incubations were terminated by the addition of 
2 vols. of cold MeOH. Because the free LTA 4 was dissolved in a mixture 
of MeOH and NaOH, the pH in the incubation medium was raised to 
7.8 after the addition of LTA4. In some experiments the optimal pH for 
the reaction was investigated, and in these xperiments the pH of the 
buffer was varied so that the final pH was in the range of 5-10. The 
pH was adjusted with acetate buffer at pH 5.0, with phosphate buffer 
at pH 6-7, with Tris buffer at pH 7.1-9.0 and with glycine buffer at pH 
10.0. In other experiments he enzyme in 50 mM Tris-HC1 (pH 7.6) 
containing 1mM DTT and 1 mg albumin was incubated at 37°C with 
LTA4 (20 nmol) added five times with 15 min between each addition. 
In separate experiments the pre-incubation time was extended to 1.5 h 
before incubation with LTA4 (20 nmol) was carried out. Incubations 
were terminated by the addition of 2 vols. of cold MeOH. 
The typical reaction mixture was kept at -20°C for 20 rain and then 
centrifuged (1,500 x g) for 10 min at 4°C to remove precipitated pro- 
teins. Lipids from the remaining supernatant were then extracted and 
prepared for RP-HPLC as previously described [1,26]. 
2.7. Reverse-phase high-performance liquid chromatography 
The extracted lipids were separated by RP-HPLC as previously de- 
scribed [1,26]. The identity of LTB 4 was ascertained aspreviously de- 
scribed [1] by characteristic ultraviolet absorbance and by chromato- 
graphic comparison with authentic LTB 4. Quantitation of LTB 4 was 
based on integration of optical density and comparison with areas 
obtained from authentic LTB 4. 
2.8. SDS-PAGE gels 
SDS-PAGE was carried out on gradient gels (8-15% polyacrylamide 
gel). Before loading of the sample to the gel, 5/11 of 2% sodium dodecyl 
sulphate, 10% glycerol, 5% 2-mercaptoethanol, 0.002% bromophenol 
blue was added per 20 ¢tl sample, and then the samples were boiled for 
2 min. 
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The gel was either silver stained as described by Blum et al. [30], or 
stained with Coomassie blue R-250. Gels stained with Coomassie blue 
were blotted to an immobilon-P transfer membrane by semi-dry blot- 
ting over 6 h. Then, the band containing the LTA4 hydrolase was cut 
out and further analyzed for the amino acid composition. 
2.9. Determination of the amino acid composition 
Immobilon strips containing the stained hydrolase protein band were 
subjected toautomated amino acid analysis using an applied Biosys- 
terns Inc. model 420A amino acid analyzer. In brief, samples were 
hydrolyzed in6 N HC1 for 75 min at 120°C followed by derivatization 
to the PITC amino acids. Samples were then quantitatively analyzed 
by RP-HPLC (note: all steps automated). Quantitation of different 
samples was made using amino acid standards and a hydrolysis test 
peptide which contained one of each of the amino acids except Glu, 
Asp, Cys and Trp. Norleucine was included as an internal standard. 
The one modification made in the determination f the mol% of each 
amino acid was that the value for Gly+Cys+Trp was taken as 10% 
(poor recoveries for Trp- and Cys-PITC are normally encountered). 
The actual Gly values were usually 2 to 10 times the amount expected 
and reflects a carry over from the SDS gel and subsequent transfer. 10% 
is the mean share for the sum of these three amino acids in the average 
protein. The determination f each amino acid is 5% as judged by 
multiple runs of the Applied Biosystems test peptide. 
3. Resu l ts  
Purification of the 100,000 x g supernatant with ammonium 
sulphate fractionation, anion-exchange chromatography (Q- 
Sepharose), hydrophobic chromatography (phenyl-Sepharose) 
and by chromatofocusing (PBE-94) resulted in a 853-fold puri- 
fication of neutrophil LTA 4 hydrolase. In contrast, only a 150- 
fold and a 200-fold purification were obtained for LTA4 hydro- 
lase from epidermis and cultured keratinocytes, respectively. 
To get a better purification of the epidermal LTA4 hydrolase, 
it was purified by ammonium sulphate fractionation followed 
by anion-exchange chromatography (Fig. 1), affinity chroma- 
tography (Fig. 2), hydrophobic chromatography (Fig. 3) and 
finally again by affinity chromatography. These purification 
steps resulted in a 396-fold purification and a yield of 7% (Table 
1). These steps resulted in a purification to almost homogeneity 
of the LTA4 hydrolase as judged by SDS-PAGE followed by 
silver staining (Fig. 4). In this method a new affinity chroma- 
tography column was introduced. It consisted of bestatin, a
LTA4 hydrolase inhibitor, coupled to Sepharose and was found 
to be the most efficient step in the purification procedure (Table 
1). It can also be seen that the loss over this column was only 
minor (Table 1), indicating that specific binding of the enzyme 
/ 
/ / 
. , [ i  
o 
.pp,,o..o. 0 loo 200 3o0 
Vo lume (ml )  
Fig. 1. Anion-exchange chromatography. The enzyme sample was ap- 
plied to a Q-Sepharose column preequilibrated with buffer A, and then 
eluted with a 300 ml linear gradient of 0-300 mM KC1 in buffer A. 1 
min fractions were collected and then assayed for LTB 4 formation 
capacity (- - -) by incubation with LTA4(30 nmol). 
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Fig. 2. Affinity chromatography. The enzyme sample was applied to a 
column with bestatin coupled to AH-Sepharose 4B preequilibrated with 
buffer B. During the application procedure the sample (10 ml) was 
allowed to re-circulate over the column for 25 min. Then the KC1 
concentration in buffer B was raised stepwise to 175 mM and 500 mM 
and 2 rain fractions were collected and assayed for LTB4 formation 
capacity (- - -) by incubation with LTA4 (30 nmol). 
to the bestatin took place. This result was supported by the 
finding of enzyme activity only in the 500 mM KC1 eluate 
fraction (Fig. 2). Furthermore, no enzyme binding took place 
when the enzyme was applied to AH-Sepharose without be- 
statin (data not shown). The specific activity in the 100,000 x g 
supernatant of human epidermis was 33.2 ng LTB4/min/mg 
(Table 1) corresponding to 0.099 nmol LTB4/min/mg. The 
LTA 4 hydrolase activity was 0.18 nmol LTB4/min/mg in cul- 
tured keratinocytes and 0.15 nmol LTB4/min/mg in neutrophils 
(data not shown). 
The pI of the purified enzyme was 5.5-5.7, as judged by 
chromatofocusing on the PBE-94 column. No differences were 
found between the epidermal, the cultured keratinocyte and the 
neutrophil derived LTA 4 hydrolases. The molecular weight of 
the enzyme was determined to be approximately 70,000 Da by 
SDS-PAGE for the epidermal (Fig. 4), the keratinocyte and 
neutrophil derived LTA 4 hydrolases (data not shown for neu- 
trophils and keratinocytes). 
The optimal pH for the transformation f LTA 4 into LTB 4 
by the epidermal LTA4 hydrolase was determined and com- 
pared with that of neutrophil derived LTA 4 hydrolase. The 
optimal pH for the epidermal LTA4 hydrolase was in the range 
of 7.5-8.5, and this was the same as for the neutrophil derived 
LTA 4 hydrolase (data not shown). 
Analysis of amino acid composition was done from immo- 
bilon-P transfer membranes. This method was used in order to 
get a higher purity of the sample, because the cultured ker- 
atinocyte LTA 4 hydrolase was only purified 200 fold. To allow 
comparison between the samples from this study, this method 
was also used in the sample from the epidermis and the neutro- 
phils: the results are shown in Table 2. Small variations between 
the three samples were found. The most prominent variation 
was the lower mol% of Pro in the hydrolase obtained from 
human epidermis and human cultured keratinocytes when com- 
pared to human neutrophils. 
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Fig. 3. Hydrophobic chromatography. The enzyme sample was applied 
to a phenyl-Sepharose column preequilibrated with buffer C. The en- 
zyme was then eluted with a 20 ml linear gradient between buffer C and 
a 0.1 M Tris-HC1 buffer, 1 mM DTT (pH 7.6). 1 min fractions were 
collected and assayed for LTA 4 hydrolase activity (- - -) by incubation 
with LTA4 (30 nmol). 
In order to elucidate whether the epidermal LTA4 hydrolase 
undergoes suicide inactivation when transforming LTA 4 into 
LTB4, LTA4 was added to the purified epidermal ETA4 hydro- 
lase repeatedly 5 times at 15 min intervals. It was found that 
the velocity of LTB 4 formation decreased each time LTA 4 was 
added, resulting in almost no new LTB 4 formation after the last 
LTA4 addition (Fig. 5). The same phenomenon was observed 
with the neutrophil LTA4 hydrolase (data not shown). The 
purified LTA 4 hydrolase was also preincubated for 1.5 h before 
LTA 4 was added and the initial velocity was determined. The 
initial velocity was not different from that found in Fig. 5 (data 
not shown). These observations suggest that the epidermal nd 
the neutrophil LTA 4 hydrolases undergo suicide inactivation 
when transforming LTA 4 into LTB 4. 
4. Discussion 
Although LTA4 hydrolase activity has previously been dem- 
onstrated in human epidermis [10,11] and in human cultured 
keratinocytes [1,3], this is the first time that the human epider- 
mal and human cultured keratinocyte LTA4 hydrolase has been 
purified and characterized. In contrast to neutrophil LTA 4 hy- 
drolase, the purification of epidermal LTA 4 hydrolase required 
the introduction ofa new non-specific affinity chromatography 
column. The affinity column which contained bestatin coupled 
to AH-Sepharose was used for the first time to purify LTA4 
hydrolase and found to be very efficient. The reason for using 
bestatin in the purification procedure is that bestatin has previ- 
ously been shown to be a potent reversible inhibitor of LTA 4 
hydrolase [31,32]. It is interesting that LTA 4 hydrolase can be 
bound to bestatin and then released by raising the KC1 concen- 
tration. The LTA 4 hydrolase nzyme has recently been de- 
scribed as a bi-functional enzyme exhibiting both hydrolase 
activity and peptidase activity [33-35]. Furthermore, sequence 
comparison with certain zinc metalloenzymes, including amin- 
opeptidase N, revealed the presence of a zinc-binding motif in 
the LTA4 hydrolase [36]. Bestatin is known as a potent inhibitor 
of many aminopeptidases, including the LTA 4 hydrolase 
[31,32], and it has been suggested that bestatin mimics the 
tetrahedral intermediate of hydrolysis using the C-2 OH to 
form a complex with the active-site Zn 2÷ of these aminopepti- 
dases [37]. In developing the affinity column, it was speculated 
that the bestatin could be coupled through its carboxy group 
to the AH-Sepharose resulting in an amide bond. This would 
keep the hydroxy group free to interact with the Zn 2+. Steric 
hindrance should be avoided since the AH-Sepharose contains 
a 6 carbon spacer arm which is very flexible. The bestatin 
column might also be useful in the separation of active LTA 4 
hydrolase from inactivated LTA4 hydrolase. With recombinant 
enzyme and enzyme purified from leukocytes it has been shown 
that the inactivation caused by LTA4 is a result of a covalent 
modification resulting in a LTA4-enzyme complex [38]. Fur- 
thermore, bestatin can inhibit this covalent modification, indi- 
cating that LTA 4 and bestatin act at the same active site of the 
enzyme. Therefore, inactivated LTA 4 hydrolase might not be 
able to bind to the bestatin column in the same way as active 
LTA 4 hydrolase. 
Human neutrophils, which have previously been used as a 
cell source for the purification of LTA4 hydrolase [16], were 
included in this study to allow a direct comparison with the 
epidermal and keratinocyte LTA4 hydrolase with a previously 
characterized nzyme. In Table 2 the findings in this study are 
compared with studies of other human cell types. In terms of 
molecular weight, the keratinocyte and epidermal LTA 4 hydro- 
lases are similar to human eutrophil, human lung and human 
recombinant hydrolases, but different from the human erythro- 
cyte hydrolase. The findings of a molecular weight of approxi- 
mately 70,000 Da is also in accordance with the findings in 
guinea pig lung [12], rat neutrophils [17] and in the human 
B-lymphocytic cell line Raji [18]. The lower molecular weight 
of the erythrocyte LTA 4 hydrolase might reflect the presence 
of different isoforms of the enzyme, as speculated by Samuels- 
Table 1 
Purification of LTA4 hydrolase from human epidermis 
Step Total protein Total activity Specific activity Y ie ld  Purification 
(mg) (ng LTB4/min) (ng LTB4/min/mg ) (%) (fold) 
100,000 x g supernatant 510.1 16953.1 33.2 100 1 
Ammonium sulphate 228.0 9152.0 40.1 54 1.2 
Q-Sepharose 13.4 4530.0 338.1 27 10.2 
Bestatin coupled to Sepharose 1.114 3989.3 3581.1 24 108 
Phenyl-Sepharose 0.206 2115.3 10268.4 12 309 
Bestatin coupled to Sepharose 0.096 1263.6 13162.5 7 396 
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Fig. 4. SDS-PAGE of the different steps in the purification of LTA4 
hydrolase from human epidermis. The gel was silver stained. Lane 1, 
100,000 xg supernatant. Lane 2, 40 70% ammonium sulphate precipi- 
tation. Lane 3, Q-Sepharose. Lane 4, bestatin coupled to AH-Sepharose 
4B (first run). Lane 5, phenyl-Sepharose. Lane 6, bestatin coupled to 
AH-Sepharose 4B (second run). 
son et al. [39]. It could also represent a breakdown product of 
the intact hydrolase, as shown by Orning et al. [40]. Recently, 
R~dmark et al. have shown that the erythrocyte LTA4 hydro- 
lase has a MW close to 70,000 Da [41]. 
The pI of 5.1-5.4 found in all three enzyme preparations was 
obtained with the SH-reducing agent DTT present in the 
buffer. The pI was not determined with the absence of SH- 
reducing agents in buffers, although Bito et al. [12] have shown 
that two catalytically active forms of the LTA4 hydrolase, de- 
pendent on the presence or absence of SH-reducing agents, are 
present in guinea pig lung. Haeggstr6m et al. have also shown 
that guinea pig liver LTA 4 hydrolase is eluted as two peaks in 
chromatofocusing differing by 0.4 in their pI if not pretreated 
with DTT [13]. The pI observed in this study is in good accord- 
ance with the findings for the LTA4 hydrolase in human neutro- 
phils and human lung (Table 2). Furthermore, no differences 
were seen in the pH optimum for the hydrolase activity of the 
enzyme derived from epidermis and neutrophils. The optimal 
pH was slightly alkaline, as has been shown with the enzyme 
from other sources (Table 2). 
In this study we also showed that the epidermal LTA 4 hydro- 
lase, similar to neutrophil and erythrocyte LTA4 hydrolase 
[2,38], undergoes suicide inactivation when transforming LTA4 
into LTB 4. This is in contrast o what has recently been re- 
ported for transformed human airway epithelial cells (BEAS- 
2B) by Bigby [24]. The human airway epithelial cell derived 
LTA4 hydrolase is also different from human leukocyte [16], 
human epidermal [10] and human erythrocyte [2] derived LTA4 
hydrolases in that it does not obey Michaelis-Menten satura- 
tion kinetics. The inactivation of the enzyme is not a result of 
degradation of the enzyme during the incubation period, while 
pre-incubation of the LTA4 hydrolase for 1.5 h did not lower 
the initial velocity of the transformation of LTA 4 into LTB 4. 
Only small variations in the amino acid composition were 
seen in the samples analyzed in this study (Table 2), and the 
determined amino acid composition bore a close resemblance 
to that determined in other studies (Table 2), although the Ser 
determined in this study was higher than determined previ- 
ously. However, the Ser level in the sample from the epidermis 
and the cultured keratinocytes was not different from that of 
human neutrophils, which was our control. Even in the study 
by Odlander et al. [18], in which two kinetic patterns of the 
enzyme were found, no difference in the amino acid composi- 
tion between the two forms was seen, and compared with our 
observations only minor differences were seen. It is interesting 
to note that the amino acid composition calculated from the 
cDNA of the LTA4 hydrolase from human spleen varies re- 
garding Asp and Glu from what has been determined in other 
studies (Table 2). 
The specific activity observed in this study is in good accord- 
ance with the 0.072 nmol LTBa/min/mg found in erythrocytes 
[2], but much lower than the 0.85 nmol LTBa/min/mg found in 
guinea pig lung [12]. 
In this study we have shown that the epidermal LTA4 hydro- 
lase bears a close resemblance in amino acid composition and 
hydrolase kinetics to the LTA 4 hydrolase obtained from almost 
all other cell types, except he airway epithelial derived LTA4 
hydrolase [24]. Because of this close resemblance to other cell 
types, and because the epidermal LTA4 hydrolase undergoes 
suicide inactivation when transforming LTA4 into LTB4, in- 
flamed human epidermis may be a good in vivo model for 
studying the transcellular metabolism in leukotriene formation. 
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Fig. 5. Purified LTA4 hydrolase was incubated with LTA 4 (20 nmol) 
added repeatedly at15 min intervals. The results represent the mean of 
two experiments. 
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Table 2 
Properties of LTA4 hydrolase from various human sources 
321 
Source Human epidermis Human cultured Human Human Human Human Human 
keratinocytes neutrophils leukocytes lung erythrocytes cDNA 2 
Molecular 69,000-70,000 69,000-70,000 69,000-70,000 68,000-70,000 68,000-71,000 
weight ~ 
pI 5.1 5.4 5.1 5.4 5.1-5.4 5.1-5.7 5.1-5.3 
pH optimum 7.5-8.5 ND 7.5 8.5 8.0-9.0 7.8-9.0 
Amino acid 
composition 
(mol %) 
As 7.0 8.9 10.4 9.8 9.9 
GI 11.0 12.2 14.0 10.1 13.0 
Ser 13.3 15.9 16.3 8.2 5.3 
Gly - - 5.5 5.3 
His 2.0 1.8 1.8 3.0 2.9 
Arg 5.7 4.9 5.9 3.2 4.1 
Thr 4.9 4.3 4.2 7.0 6.6 
Ala 9.7 6.1 6.0 6.7 6.8 
Pro 2.5 3.6 6.9 6.3 6.5 
Tyr 3.6 2.9 3.4 3.4 3.7 
Val 6.7 4.4 3.7 7.0 5.7 
Met 2.7 1.9 - 1.6 1.9 
Ile 5.6 4.4 3.2 3.9 5.0 
Leu 11.8 10.1 6.7 11.8 12.0 
Phe 3.5 4.1 2.1 4.8 4.7 
Lys - 4.6 5.2 7.6 6.8 
Cys . . . .  
Yyr . . . .  
Reference This study This study This study 16 14 
54,000-1,0003 69,154 
4.9 + 0.2 6.1 
7.0-8.0 ND 
ND 
9.0 
10.9 
7.4 
4.9 
2.6 
3.8 
6.6 
6.2 
5.7 
3.6 
6.2 
1.8 
5.1 
11.3 
4.4 
6.6 
1.8 
2.1 
2 20 
IDetermined by SDS-PAGE. 
2Calculated from human cDNA. 
3May represent a break down product (see text). 
ND = Not determined. 
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